What is HC Wainwright’s Estimate for NRIX FY2026 Earnings?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Nurix Therapeutics in a report issued on Tuesday, July 1st. HC Wainwright analyst R. Burns anticipates that the company will earn ($3.33) per share for the year. HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. During the same quarter in the previous year, the firm posted ($0.76) EPS.

A number of other analysts have also recently commented on NRIX. Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. Needham & Company LLC reiterated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Leerink Partnrs raised shares of Nurix Therapeutics to a “hold” rating in a report on Monday, March 17th. Wells Fargo & Company lowered their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Finally, Stifel Nicolaus dropped their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.18.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $12.44 on Wednesday. The stock has a market cap of $948.43 million, a P/E ratio of -4.44 and a beta of 2.15. The stock’s fifty day moving average is $11.07 and its 200 day moving average is $14.21. Nurix Therapeutics has a one year low of $8.18 and a one year high of $29.56.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE increased its stake in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Nurix Therapeutics during the fourth quarter valued at $28,000. Aquatic Capital Management LLC bought a new position in Nurix Therapeutics during the fourth quarter valued at $87,000. Exchange Traded Concepts LLC grew its stake in shares of Nurix Therapeutics by 38.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company’s stock worth $109,000 after buying an additional 2,562 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Nurix Therapeutics in the 1st quarter worth about $122,000.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 6,198 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer owned 33,724 shares in the company, valued at $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider directly owned 61,516 shares in the company, valued at $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,013 shares of company stock worth $137,096. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.